About Cidara Therapeutics (NASDAQ:CDTX)
Cidara Therapeutics, Inc., formerly K2 Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections. Its product portfolio consists of over two formulations of its echinocandin, CD101. CD101 IV is a long-acting therapy for the treatment and prevention of serious, invasive fungal infections. CD101 topical, its second product candidate, is being developed for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC), a prevalent mucosal infection. Its immunotherapy technology platform, Cloudbreak, is used to create compounds designed to direct a patient's immune cells to attack and eliminate pathogens that cause infectious disease. The Company is also developing CD201, its bispecific antimicrobial immunotherapy.
Industry, Sector and Symbol:
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Sector: Bio Therapeutic Drugs
- Symbol: NASDAQ:CDTX
- CUSIP: N/A
- Web: www.cidara.com
- Debt-to-Equity Ratio: 0.16%
- Current Ratio: 7.69%
- Quick Ratio: 7.69%
Sales & Book Value:
- Annual Sales: N/A
- Price / Sales: N/A
- Book Value: $2.50 per share
- Price / Book: 3.14
- Trailing EPS: ($3.39)
- Net Income: ($48,160,000.00)
- Return on Equity: -82.17%
- Return on Assets: -65.11%
- Employees: 60
- Outstanding Shares: 20,240,000
Frequently Asked Questions for Cidara Therapeutics (NASDAQ:CDTX)
What is Cidara Therapeutics' stock symbol?
Cidara Therapeutics trades on the NASDAQ under the ticker symbol "CDTX."
How were Cidara Therapeutics' earnings last quarter?
Cidara Therapeutics, Inc. (NASDAQ:CDTX) posted its quarterly earnings data on Wednesday, November, 8th. The biotechnology company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.94) by $0.21. View Cidara Therapeutics' Earnings History.
Where is Cidara Therapeutics' stock going? Where will Cidara Therapeutics' stock price be in 2017?
10 brokers have issued 1 year price objectives for Cidara Therapeutics' stock. Their predictions range from $7.25 to $20.00. On average, they anticipate Cidara Therapeutics' share price to reach $13.85 in the next year. View Analyst Ratings for Cidara Therapeutics.
What are Wall Street analysts saying about Cidara Therapeutics stock?
Here are some recent quotes from research analysts about Cidara Therapeutics stock:
- 1. According to Zacks Investment Research, "Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California. " (10/25/2017)
- 2. Needham & Company LLC analysts commented, "Cidara mgmt provided a corporate update at an Investor Day in NYC last week and we separately hosted a series of mtgs w/ investors. Mgmt reiterated guidance for top-line results from ongoing Phase 2 trial of CD101 in Invasive Candida infections in 4Q17. The trial is expected to serve as the first of two registration trials. Given discontinuation of CD101 Vulvovaginal Candidiasis program, mgmt introduced plans to instead accelerate development in antifungal prophylaxis. KOLs highlighted differentiation from other echinocandins, w/ emphasis on PK/PD profile and opportunity for better clinical outcomes. New details around Cloudbreak candidates were also announced, although clinical testing not expected until 2018. Stock is attractive ahead of Phase 2 CD101 results later this year (EV $15M)." (4/10/2017)
- 3. Cantor Fitzgerald analysts commented, "PD/PK Data Points to Success in Phase 2: Presentations reviewed the potency of CD101 against Candida and Aspergillus species as well as broad and sustained tissue distribution. We found the PK/PD optimized dosing data persuasive as it clearly demonstrates, effective AUC/MIC levels at the 400mg once-weekly over three weeks and 400mg loading dose followed by 200mg once weekly for two weeks, paralleling the two dosing regimens being studied in the Phase 2. We also note the potential for subcutaneous dosing, which could enhance the commercial story. We have increased our probability of success from 45% to 50%. Breadth of Cloudbreak Platform Highlighted: In addition to the antibacterial CD201, currently working through pre-IND studies, early in vivo/in vitro data was presented on a new antifungal asset." (4/7/2017)
- 4. HC Wainwright analysts commented, "This is why there are still no topical echinocandins. Yesterday, before markets opened, Cidara reported results of the Phase 2 RADIANT study in women with vulvovaginal candidiasis (VVC) in which neither topical formulation of CD101 (gel or ointment) achieved efficacy levels comparable to standard of care (SOC) oral fluconazole. As a result, Cidara has discontinued further development of topical CD101 for VVC. The outcome of RADIANT came as a surprise to both management and us, given the potent fungicidal properties of CD101 demonstrated in vitro (even at vaginal pH of 4.0), and that both formulations had outperformed fluconazole in preclinical models' Focus now squarely on STRIVE readout in 4Q17. Recall, STRIVE is a POC Phase 2 candidemia study of CD101 IV vs. Cancidas (IV caspofungin; the leading on-market echinocandin) followed by oral fluconazole step-down (NCT02734862). Coprimary efficacy endpoints are mycological eradication (laboratory cure) and resolution of systemic signs of candidemia (clinical cure)." (2/22/2017)
Who are some of Cidara Therapeutics' key competitors?
Some companies that are related to Cidara Therapeutics include BioSpecifics Technologies Corp (BSTC), Merus N.V. (MRUS), Geron Corporation (GERN), Edge Therapeutics (EDGE), Alcobra (ADHD), Circassia Pharmaceuticals PLC (CIR), Pieris Pharmaceuticals (PIRS), Arrowhead Pharmaceuticals (ARWR), Ardelyx (ARDX), Oxford BioMedica plc (OXB), Catalyst Pharmaceuticals (CPRX), Vascular Biogenics (VBLT), Faron Pharmaceuticals Oy (FARN), Ovid Therapeutc (OVID), Vital Therapies (VTL), Athersys (ATHX), Chimerix (CMRX) and Threshold Pharmaceuticals (MTEM).
Who are Cidara Therapeutics' key executives?
Cidara Therapeutics' management team includes the folowing people:
- Scott M. Rocklage Ph.D., Chairman of the Board (Age 61)
- Jeffrey L. Stein Ph.D., President, Chief Executive Officer, Director (Age 62)
- Matthew W. Onaitis J.D., Chief Financial Officer, Principal Financial Officer, General Counsel, Secretary (Age 45)
- Kenneth Bartizal Ph.D., Chief Development Officer (Age 63)
- Paul Daruwala, Chief Commercial Officer (Age 46)
- Kevin M. Forrest Ph.D., Chief Strategy Officer (Age 39)
- Taylor Sandison M.D., Chief Medical Officer
- Daniel D. Burgess, Director (Age 55)
- Timothy R. Franson M.D., Director (Age 65)
- Robert J. Perez, Director (Age 52)
When did Cidara Therapeutics IPO?
(CDTX) raised $60 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow Life Sciences, Needham and BTIG were co-managers.
Who owns Cidara Therapeutics stock?
Cidara Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include
BB BIOTECH AG
(11.05%), JPMorgan Chase & Co. (0.24%), Boothbay Fund Management LLC (0.14%), Raymond James Financial Services Advisors Inc. (0.14%) and OxFORD Asset Management LLP (0.11%). Company insiders that own Cidara Therapeutics stock include Jeffrey Stein, Kevin Forrest, Target N V Biotech and Taylor Sandison. View Institutional Ownership Trends for Cidara Therapeutics.
Who sold Cidara Therapeutics stock? Who is selling Cidara Therapeutics stock?
Who bought Cidara Therapeutics stock? Who is buying Cidara Therapeutics stock?
Cidara Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., OxFORD Asset Management LLP and Raymond James Financial Services Advisors Inc.. Company insiders that have bought Cidara Therapeutics stock in the last two years include Jeffrey Stein, Kevin Forrest, Target N V Biotech and Taylor Sandison. View Insider Buying and Selling for Cidara Therapeutics.
How do I buy Cidara Therapeutics stock?
Shares of Cidara Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cidara Therapeutics' stock price today?
One share of Cidara Therapeutics stock can currently be purchased for approximately $7.85.
How big of a company is Cidara Therapeutics?
Cidara Therapeutics has a market capitalization of $157.86 million. The biotechnology company earns ($48,160,000.00) in net income (profit) each year or ($3.39) on an earnings per share basis. Cidara Therapeutics employs 60 workers across the globe.
How can I contact Cidara Therapeutics?
Cidara Therapeutics' mailing address is 6310 Nancy Ridge Dr Ste 101, SAN DIEGO, CA 92121-3209, United States. The biotechnology company can be reached via phone at +1-858-7526170 or via email at [email protected]
MarketBeat Community Rating for Cidara Therapeutics (NASDAQ CDTX)MarketBeat's community ratings are surveys of what our community members think about Cidara Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Cidara Therapeutics (NASDAQ:CDTX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 1 Hold Rating, 8 Buy Ratings, 1 Strong Buy Rating|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$13.85 (76.43% upside)|
Consensus Price Target History for Cidara Therapeutics (NASDAQ:CDTX)
Analysts' Ratings History for Cidara Therapeutics (NASDAQ:CDTX)
(Data available from 11/18/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|11/9/2017||HC Wainwright||Boost Price Target||Buy||$14.00 -> $16.00||N/A|
|9/26/2017||Cantor Fitzgerald||Reiterated Rating||Buy||$15.00||Low|
|8/11/2017||WBB Securities||Upgrade||Sell -> Hold||Low|
|4/29/2017||BTIG Research||Reiterated Rating||Buy||$15.00 -> $20.00||Low|
|4/20/2017||Raymond James Financial, Inc.||Initiated Coverage||Strong-Buy||$14.00||High|
|4/12/2017||Ladenburg Thalmann Financial Services||Initiated Coverage||Buy -> Buy||$11.25||Low|
|4/10/2017||Needham & Company LLC||Reiterated Rating||Buy||$10.00||Medium|
|3/24/2017||Jefferies Group LLC||Reiterated Rating||Buy||$15.00||High|
|12/21/2016||Leerink Swann||Initiated Coverage||Outperform||$17.00||N/A|
Earnings History and Estimates Chart for Cidara Therapeutics (NASDAQ:CDTX)
Earnings History by Quarter for Cidara Therapeutics (NASDAQ CDTX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/8/2017||Q3 2017||($0.94)||($0.73)||$0.18 million||View||N/A|
|8/9/2017||Q2 2017||($0.91)||($0.99)||$0.25 million||View||N/A|
Earnings Estimates for Cidara Therapeutics (NASDAQ:CDTX)
2017 EPS Consensus Estimate: ($3.45)
2018 EPS Consensus Estimate: ($2.86)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Cidara Therapeutics (NASDAQ:CDTX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Cidara Therapeutics (NASDAQ CDTX)
Insider Ownership Percentage: 18.90%
Institutional Ownership Percentage: 66.11%
Insider Trades by Quarter for Cidara Therapeutics (NASDAQ CDTX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|11/15/2017||Target N V Biotech||Major Shareholder||Buy||60,000||$7.57||$454,200.00|| |
|9/12/2017||Jeffrey Stein||CEO||Buy||7,350||$6.79||$49,906.50|| |
|6/7/2017||Taylor Sandison||Insider||Buy||20,000||$5.90||$118,000.00|| |
|6/5/2017||Jeffrey Stein||CEO||Buy||15,000||$5.95||$89,250.00|| |
|3/31/2017||Jeffrey Stein||CEO||Buy||12,900||$7.75||$99,975.00|| |
|3/31/2017||Kevin Forrest||Insider||Buy||12,500||$7.75||$96,875.00|| |
|5/20/2016||Jeffrey Stein||CEO||Buy||4,310||$11.51||$49,608.10|| |
|5/20/2016||Kevin Forrest||CFO||Buy||4,356||$11.53||$50,224.68|| |
|11/25/2015||Jeffrey Stein||CEO||Buy||6,700||$15.09||$101,103.00|| |
|11/23/2015||Kevin Forrest||CFO||Buy||7,087||$14.23||$100,848.01|| |
|4/20/2015||Timothy R Franson||Director||Buy||4,000||$16.00||$64,000.00|| |
Headline Trends for Cidara Therapeutics (NASDAQ:CDTX)
Latest Headlines for Cidara Therapeutics (NASDAQ CDTX)
|Cidara Therapeutics, Inc. (CDTX) Major Shareholder Target N. V. Biotech Buys 60,000 Shares|
www.americanbankingnews.com - November 16 at 4:24 PM
|Cidara Therapeutics Named a San Diego Metro Area 2017 Top Workplace|
finance.yahoo.com - November 13 at 11:11 PM
|Cidara Therapeutics, Inc. (CDTX) Expected to Earn FY2017 Earnings of ($3.14) Per Share|
www.americanbankingnews.com - November 13 at 3:58 AM
|Cidara Therapeutics, Inc. (CDTX) Forecasted to Earn Q3 2018 Earnings of ($0.72) Per Share|
www.americanbankingnews.com - November 10 at 4:20 PM
|Edited Transcript of CDTX earnings conference call or presentation 8-Nov-17 9:05pm GMT|
finance.yahoo.com - November 9 at 7:53 PM
|Cidara Therapeutics, Inc. (CDTX) Posts Earnings Results, Beats Expectations By $0.21 EPS|
www.americanbankingnews.com - November 9 at 12:44 AM
|5 Biotech Stocks Well Poised to Surpass Expectations in Q3|
finance.yahoo.com - November 7 at 8:00 PM
|Cidara Therapeutics, Inc. (CDTX) Receives Average Recommendation of "Buy" from Brokerages|
www.americanbankingnews.com - November 6 at 5:48 PM
|Cidara Therapeutics to Report Third Quarter 2017 Financial Results and Provide Corporate Update|
finance.yahoo.com - November 1 at 5:51 PM
|Contrasting ADMA Biologics (ADMA) and Cidara Therapeutics (CDTX)|
www.americanbankingnews.com - October 26 at 11:36 AM
|Cidara Therapeutics, Inc. (CDTX) Raised to Buy at Zacks Investment Research|
www.americanbankingnews.com - October 25 at 5:26 PM
|QURE On Fast Track, Music To CNCE's Ears, CRBP Gets A Facelift, OBLN Deflated|
www.rttnews.com - October 19 at 10:36 PM
|Cidara Therapeutics (CDTX) Prices $20M Private Placement of Common Stock|
www.streetinsider.com - October 19 at 10:36 PM
|Cidara Therapeutics Announces Pricing of $20 Million Private Placement of Common Stock|
finance.yahoo.com - October 19 at 5:34 PM
|Contrasting Spark Therapeutics (ONCE) & Cidara Therapeutics (CDTX)|
www.americanbankingnews.com - October 19 at 12:16 AM
|Cidara Therapeutics, Inc. (CDTX) Receives Consensus Rating of "Buy" from Analysts|
www.americanbankingnews.com - October 12 at 6:56 PM
|Cidara Therapeutics (CDTX) & Aradigm Corporation (ARDM) Critical Analysis|
www.americanbankingnews.com - October 10 at 9:07 AM
|Cidara Therapeutics, Inc. (CDTX) Stock Rating Reaffirmed by Cantor Fitzgerald|
www.americanbankingnews.com - September 27 at 6:10 PM
|Cidara Therapeutics Announces Presentations at IDWeek 2017 and the 8th Trends in Medical Mycology Meeting|
finance.yahoo.com - September 25 at 7:44 PM
|Cidara Therapeutics to Present at Two Upcoming Conferences|
finance.yahoo.com - September 18 at 8:37 PM
|Cidara Therapeutics, Inc. (CDTX) CEO Acquires $49,906.50 in Stock|
www.americanbankingnews.com - September 12 at 8:24 PM
|Cidara Therapeutics to Participate in Keynote Panel Discussion at the 2017 World Antimicrobial Resistance Congress|
finance.yahoo.com - September 7 at 5:09 PM
|Antimicrobials Working Group Member Companies Announce Partnership and Exclusive Pricing Program|
www.prnewswire.com - September 6 at 10:05 PM
|Cidara Therapeutics, Inc. (CDTX) Short Interest Down 53.3% in August|
www.americanbankingnews.com - August 28 at 1:20 AM
|Cidara Therapeutics, Inc. (CDTX) Receives Consensus Recommendation of "Buy" from Analysts|
www.americanbankingnews.com - August 23 at 6:46 PM
|Brokers Issue Forecasts for Cidara Therapeutics, Inc.'s Q3 2017 Earnings (CDTX)|
www.americanbankingnews.com - August 16 at 7:22 AM
|Equities Analysts Offer Predictions for Cidara Therapeutics, Inc.'s FY2018 Earnings (CDTX)|
www.americanbankingnews.com - August 14 at 9:22 AM
|Leerink Swann Comments on Cidara Therapeutics, Inc.'s Q3 2017 Earnings (NASDAQ:CDTX)|
www.americanbankingnews.com - August 14 at 3:34 AM
|Cidara Therapeutics' (CDTX) Overweight Rating Reiterated at Cantor Fitzgerald|
www.americanbankingnews.com - August 12 at 6:34 AM
|Cidara Therapeutics, Inc. (CDTX) Upgraded to "Hold" at WBB Securities|
www.americanbankingnews.com - August 11 at 7:32 PM
|Cantor Fitzgerald Analysts Give Cidara Therapeutics, Inc. (CDTX) a $15.00 Price Target|
www.americanbankingnews.com - August 10 at 6:20 PM
|Cidara Therapeutics Inc (NASDAQ:CDTX) Announces Quarterly Earnings Results|
www.americanbankingnews.com - August 9 at 11:58 PM
|Cidara Therapeutics reports 2Q loss|
finance.yahoo.com - August 9 at 10:17 PM
|Cidara Therapeutics Announces Publication of Results from In Vivo Study Investigating Novel Antifungal CD101 in Intra-Abdominal Candidiasis (IAC)|
finance.yahoo.com - August 1 at 3:34 PM
|Cidara Therapeutics, Inc. (NASDAQ:CDTX) Given Average Recommendation of "Buy" by Analysts|
www.americanbankingnews.com - July 29 at 4:43 PM
|Cidara Therapeutics to Participate in Anti-Infectives Panel Discussion at the 2017 Infectious Diseases Summit|
finance.yahoo.com - July 6 at 6:16 PM
|Cidara Therapeutics, Inc. (CDTX) Given Average Rating of "Buy" by Brokerages|
www.americanbankingnews.com - July 4 at 5:22 PM
|CIDARA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement|
biz.yahoo.com - March 31 at 9:23 PM
|Cidara Therapeutics (CDTX) Secures $6.9M Grant from CARB-X|
www.streetinsider.com - March 31 at 2:39 AM
|Cidara Therapeutics Awarded $6.9 Million Grant from CARB-X to Advance Development of its First CloudbreakTM Antibiotic Immunotherapy|
us.rd.yahoo.com - March 30 at 4:38 PM
|Cidara Therapeutics upgraded by WBB Securities|
us.rd.yahoo.com - February 23 at 4:11 PM
|Cidara Yeast Infection Gelm Fails Phase 2 Trial|
us.rd.yahoo.com - February 23 at 4:11 PM
|Cidara Therapeutics (CDTX) Says Phase 2 RADIANT Trial of CD101 Didn't Show Sufficient Efficacy|
www.streetinsider.com - February 22 at 12:11 PM
|Cidara Yeast Infection Gel Fails Phase 2 (CDTX)|
www.investopedia.com - February 22 at 12:11 PM
|CIDARA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibi|
biz.yahoo.com - February 21 at 2:26 PM
|8:32 am Cidara Therapeutics announces data from preclinical and clinical studies evaluating its novel echinocandin antifungal CD101 in the journal Antimicrobial Agents and Chemotherapy|
us.rd.yahoo.com - December 15 at 3:14 AM
|Cidara Provides Corporate Update and Reports Third Quarter 2016 Financial Results|
www.nasdaq.com - November 10 at 10:11 PM
|Cidara Therapeutics Announces Data from Studies of Novel Antifungal CD101 to be Presented at ACCP and IDWeek Annual Meetings|
www.businesswire.com - October 25 at 8:59 AM
|Cidara Therapeutics (CDTX) Prices 2.48M Common Stock Offering at $10.10/Share|
www.streetinsider.com - October 8 at 8:52 AM
|CIDARA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Sta|
biz.yahoo.com - October 8 at 8:52 AM
Cidara Therapeutics (NASDAQ CDTX) Chart for Saturday, November, 18, 2017